Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatasePaul Harmatz, Celeste Decker, David Ketteridge et al.|Molecular Genetics and Metabolism|2008Cited by 216
Replacing acid α-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibersNina Raben, Paul H. Plötz, Tokiko Fukuda et al.|Molecular Therapy|2004Cited by 138
Induction of Tolerance to a Recombinant Human Enzyme, Acid Alpha-Glucosidase, in Enzyme Deficient Knockout MiceNina Raben, Paul H. Plötz, Kanneboyina Nagaraju et al.|Transgenic Research|2003Cited by 32
Neuronal-specific impairment of heparan sulfate degradation in Drosophila reveals pathogenic mechanisms for Mucopolysaccharidosis type IIIADani L. Webber, Louise V. O’Keefe, Amanda Choo et al.|Experimental Neurology|2018Cited by 19
<scp><i>Drosophila melanogaster</i></scp>models of<scp>MPS IIIC</scp>(<scp><i>Hgsnat</i></scp>‐deficiency) highlight the role of glia in disease presentationLaura J. Hewson, Louise V. O’Keefe, Amanda Choo et al.|Journal of Inherited Metabolic Disease|2024Cited by 3